Ferulic acid-loaded nanostructure prevents morphine reinstatement: the involvement of dopamine system, NRF2, and ΔFosB in the striatum brain area of rats

Milanesi, Laura Hautrive; Rossato, Domênika Rubert; Rosa, Jéssica Leandra Oliveira da; D’avila, Lívia Ferraz; Metz, Vinícia Garzella; Rampelotto, Camila Reck; Pereira, Viviane Gonçalves; Schaffazick, Scheila Rezende; Silva, Cristiane de Bona da; Bürger, Marilise Escobar

doi:10.1007/s00210-023-02420-w

Cited by 4 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FA‐Nc improved FA's therapeutic potential in inhibiting morphine‐induced oxidative stress, regulating dopaminergic neurotransmission and deactivating the chronic addiction cascade, leading to significant mitigation in morphine craving. [ 250 ] The suppression of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor (AMPAR), which mediates the rapid propagation of excitatory signals, has shown promising results in alleviating morphine craving. Topiramate (TPM), an AMPAR antagonist, is widely used for treating epilepsy, bipolar disorder and psychostimulant addiction, despite its high risk of impairing cognitive functions.…”

Section: Pd Approaches: Nanomedicines For Treating Anesthesia‐related...mentioning

confidence: 99%

Nanotherapeutics for Alleviating Anesthesia‐Associated Complications

Lu,

Wei,

Shi

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Current management of anesthesia‐associated complications falls short in terms of both efficacy and safety. Nanomaterials with versatile properties and unique nano‐bio interactions hold substantial promise as therapeutics for addressing these complications. This review conducts a thorough examination of the existing nanotherapeutics and highlights the strategies for developing prospective nanomedicines to mitigate anesthetics‐related toxicity. Initially, general, regional, and local anesthesia along with the commonly used anesthetics and related prevalent side effects are introduced. Furthermore, employing nanotechnology to prevent and alleviate the complications of anesthetics is systematically demonstrated from three aspects, that is, developing 1) safe nano‐formulization for anesthetics; 2) nano‐antidotes to sequester overdosed anesthetics and alter their pharmacokinetics; 3) nanomedicines with pharmacodynamic activities to treat anesthetics toxicity. Finally, the prospects and challenges facing the clinical translation of nanotherapeutics for anesthesia‐related complications are discussed. This work provides a comprehensive roadmap for developing effective nanotherapeutics to prevent and mitigate anesthesia‐associated toxicity, which can potentially revolutionize the management of anesthesia complications.

show abstract

Section: Pd Approaches: Nanomedicines For Treating Anesthesia‐related...mentioning

confidence: 99%